While we are focused on developing the best possible cannabinoid products, we believe that improving the health and wellbeing of patients goes beyond this. That’s why we are committed to investing in research and development.
In addition to continuing to invest in research and development in-house, we understand that a strong partnership with clinicians and researchers is key to expanding the industry and helping people.
By prioritising research, we have the power to discover the full potential of cannabinoid medicines in treating diseases and improving lives. That’s why we partner with key universities to undertake cannabis research and support their clinical trial programs.
This review of 49 studies assesses the use of medicinal cannabis for anxiety-related disorders. The available evidences demonstrates there is a potential benefit of cannabinoids in reducing anxiety behaviors relevant to disorders such as PTSD, GAD, PD, OCD, and SAD, with no anxiogenic effects. The authors emphasise the potential value and need for further study of CBD in the treatment of anxiety disorders.
The review of 24 reports evaluates the use of medicinal cannabis for psychiatric, movement and neurodegenerative disorders. The available evidences suggest there is a potential benefit of cannabinoids for those diseases however further research is required to confirm its efficacy.
We currently have a research partnership with the Hunter Medical Research Institute, a partner of the University of Newcastle. For more information about how to become a partner please contact us.